Monali Desai

4.4k total citations · 1 hit paper
20 papers, 1.6k citations indexed

About

Monali Desai is a scholar working on Oncology, Genetics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Monali Desai has authored 20 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Genetics and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Monali Desai's work include Cancer Immunotherapy and Biomarkers (8 papers), Chronic Lymphocytic Leukemia Research (7 papers) and CAR-T cell therapy research (5 papers). Monali Desai is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), Chronic Lymphocytic Leukemia Research (7 papers) and CAR-T cell therapy research (5 papers). Monali Desai collaborates with scholars based in United States, Germany and Australia. Monali Desai's co-authors include Elisa Cerri, Sari H. Enschede, Andrew W. Roberts, Matthew S. Davids, John F. Seymour, John F. Gerecitano, William G. Wierda, Shekman Wong, Rod Humerickhouse and John M. Pagel and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Monali Desai

19 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

2015 1.3k citations Andrew W. Roberts, Matthew S. Davids et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Monali Desai United States	7	950	617	533	446	402	20	1.6k
Lori A. Gressick Australia	10	1.0k 1.1×	772 1.3×	605 1.1×	447 1.0×	474 1.2×	13	1.7k
Mehrdad Mobasher United States	16	903 1.0×	672 1.1×	274 0.5×	345 0.8×	433 1.1×	39	1.4k
Stephen E. Spurgeon United States	25	1.6k 1.7×	1.3k 2.1×	794 1.5×	543 1.2×	690 1.7×	98	2.4k
Sílvia Marcé Spain	12	1.1k 1.2×	877 1.4×	458 0.9×	240 0.5×	306 0.8×	20	1.6k
Monica Else United Kingdom	22	1.6k 1.7×	1.2k 1.9×	428 0.8×	320 0.7×	403 1.0×	42	2.0k
Peter Sportelli United States	18	737 0.8×	694 1.1×	652 1.2×	332 0.7×	431 1.1×	81	1.5k
Nicole Lamanna United States	21	1.4k 1.5×	1.1k 1.8×	269 0.5×	428 1.0×	343 0.9×	113	1.8k
Ilaria Del Giudice Italy	24	1.5k 1.6×	1.3k 2.0×	331 0.6×	305 0.7×	408 1.0×	82	1.9k
Virginia Kelly United States	16	624 0.7×	316 0.5×	322 0.6×	453 1.0×	394 1.0×	34	1.2k
Amber Gordon United States	8	1.2k 1.2×	792 1.3×	432 0.8×	357 0.8×	340 0.8×	14	1.5k

Countries citing papers authored by Monali Desai

Since Specialization

Citations

This map shows the geographic impact of Monali Desai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Monali Desai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Monali Desai more than expected).

Fields of papers citing papers by Monali Desai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Monali Desai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Monali Desai. The network helps show where Monali Desai may publish in the future.

Co-authorship network of co-authors of Monali Desai

This figure shows the co-authorship network connecting the top 25 collaborators of Monali Desai. A scholar is included among the top collaborators of Monali Desai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Monali Desai. Monali Desai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Weber, Jeffrey S., Richard D. Carvajal, Inderjit Mehmi, et al.. (2023). ARTISTRY-6: Nemvaleukin alfa monotherapy in patients with advanced mucosal and cutaneous melanoma.. Journal of Clinical Oncology. 41(16_suppl). TPS9592–TPS9592. 2 indexed citations

Vaishampayan, Ulka N., Shipra Gandhi, Anna Spreafico, et al.. (2022). Nemvaleukin alfa combination therapy for gastrointestinal (GI) cancers: Preclinical evidence and clinical data from the ARTISTRY-1 trial.. Journal of Clinical Oncology. 40(4_suppl). 659–659.

Winer, Ira, Ulka N. Vaishampayan, Lucy Gilbert, et al.. (2022). Clinical outcomes of ovarian cancer patients treated with the novel engineered cytokine nemvaleukin alfa in combination with the PD-1 inhibitor pembrolizumab: recent data from ARTISTRY-1 (077). Gynecologic Oncology. 166. S49–S49. 8 indexed citations

Calvo, Emiliano, Valentina Boni, Arvind Chaudhry, et al.. (2022). Nemvaleukin alfa in patients with advanced renal cell carcinoma: ARTISTRY-1.. Journal of Clinical Oncology. 40(6_suppl). 330–330. 2 indexed citations

Weber, Jeffrey S., Richard D. Carvajal, Omid Hamid, et al.. (2022). ARTISTRY-6: Nemvaleukin alfa monotherapy in patients with advanced mucosal and cutaneous melanoma.. Journal of Clinical Oncology. 40(16_suppl). TPS9609–TPS9609. 1 indexed citations

Herzog, Thomas J., John L. Hays, Kathleen N. Moore, et al.. (2022). TP025/#1399 Artistry-7: phase 3 multicenter study of nemvaleukin alfa plus pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. A235.2–A235. 1 indexed citations

Herzog, Thomas J., Kathleen N. Moore, Panagiotis A. Konstantinopoulos, et al.. (2022). ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa in combination with pembrolizumab versus chemotherapy in patients (pts) with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.. Journal of Clinical Oncology. 40(16_suppl). TPS5609–TPS5609. 3 indexed citations

Spadaccini, Marco, Andrea Iannone, Roberta Maselli, et al.. (2021). OC.02.6 ARTIFICIAL INTELLIGENCE VERSUS ADVANCED IMAGING FOR DETECTION OF COLORECTAL NEOPLASIA: A NETWORK METAANALYSIS. Digestive and Liver Disease. 53. S99–S100. 1 indexed citations

Hamid, Omid, Stephen V. Liu, Ralph V. Boccia, et al.. (2021). Selection of the recommended phase 2 dose (RP2D) for subcutaneous nemvaleukin alfa: ARTISTRY-2.. Journal of Clinical Oncology. 39(15_suppl). 2552–2552. 10 indexed citations

10.

Simone, Giuseppe, Umberto Anceschi, Aldo Brassetti, et al.. (2019). MP38-17 VALIDATION OF THE COBRA NOMOGRAM FOR THE PREDICTION OF CANCER SPECIFIC SURVIVAL IN PATIENTS WITH BLADDER CANCER TREATED WITH RADICAL CYSTECTOMY. The Journal of Urology. 201(Supplement 4). 1 indexed citations

11.

Davids, Matthew S., Michael Hallek, William G. Wierda, et al.. (2018). Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. Clinical Cancer Research. 24(18). 4371–4379. 113 indexed citations

12.

Davids, Matthew S., John F. Seymour, Andrew W. Roberts, et al.. (2018). Mitigation of tumor lysis syndrome (TLS) complications with venetoclax (VEN) in CLL.. Journal of Clinical Oncology. 36(15_suppl). 7526–7526. 1 indexed citations

13.

Cacciamani, Giovanni, Matthew Winter, Luis G. Medina, et al.. (2018). RRC-pentafecta: A proposal for standardization of outcomes reporting following robot assisted radical cystectomy. European Urology Supplements. 17(2). e517–e518. 1 indexed citations

14.

Lü, Peng, Roy Fleischmann, C. Martin Curtis, et al.. (2017). Safety and pharmacodynamics of venetoclax (ABT-199) in a randomized single and multiple ascending dose study in women with systemic lupus erythematosus. Lupus. 27(2). 290–302. 21 indexed citations

15.

Cheson, Bruce D., Sari H. Enschede, Elisa Cerri, et al.. (2017). Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents. The Oncologist. 22(11). 1283–1291. 49 indexed citations

16.

Seymour, John F., Matthew S. Davids, Andrew W. Roberts, et al.. (2016). Safety Profile of Venetoclax Monotherapy in Patients with Chronic Lymphocytic Leukemia. Blood. 128(22). 4395–4395. 6 indexed citations

17.

Davids, Matthew S., Jalaja Potluri, Elisa Cerri, et al.. (2016). Integrated safety analysis of venetoclax monotherapy in chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology. 34(15_suppl). 7528–7528. 4 indexed citations

18.

Roberts, Andrew W., Matthew S. Davids, John M. Pagel, et al.. (2015). Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. New England Journal of Medicine. 374(4). 311–322. 1337 indexed citations breakdown →

19.

Stewart, Jane, William J. Breslin, Bruce Beyer, et al.. (2015). Birth Control in Clinical Trials: Industry Survey of Current Use Practices, Governance, and Monitoring. Therapeutic Innovation & Regulatory Science. 50(2). 155–168. 17 indexed citations

20.

Schlicher, Robyn K., Monali Desai, Mark R. Prausnitz, & Robert P. Apkarian. (2002). Characterization of ultrasound-mediated cellular effects. The Journal of the Acoustical Society of America. 112(5_Supplement). 2339–2339. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact